Imugene Highlights Recent Achievements and Looks Ahead to
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio....
Stay updated with breaking news from Information Summaries. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio....
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today published its first ever set of treatment...
<p><em>New NCCN Guidelines for Neuroblastoma address the importance and impact of risk stratification for treating one of the more common types of pediatric solid tumors; includes vanguard treatment recommendations involving multimodality treatment for high-risk disease.</em></p>
New NCCN Guidelines for Neuroblastoma address the importance and impact of risk stratification for treating one of the more common types of pediatric solid tumo
New NCCN Guidelines for Neuroblastoma address the importance and impact of risk stratification for treating one of the more common types of pediatric solid tumo